Lipum AB (publ)
Developing first-in-class antibody drug candidate for chronic inflammatory diseases.
Overview
- 5–9
- Employees
- 750–999K SEK
- Revenue
- 2010
- Founded
Key Decision Makers
Ola Sandborgh
CEO
Description
Lipum AB (publ) is a clinical-phase biopharmaceutical company focused on developing novel treatments for chronic inflammatory diseases. Their lead drug candidate is SOL-116, a humanized monoclonal antibody designed to offer a unique mechanism of action. SOL-116 targets the Bile Salt-Stimulated Lipas...